Key Insights

Highlights

Success Rate

90% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

6.1%

3 terminated out of 49 trials

Success Rate

90.0%

+3.5% vs benchmark

Late-Stage Pipeline

33%

16 trials in Phase 3/4

Results Transparency

30%

8 of 27 completed with results

Key Signals

8 with results90% success

Data Visualizations

Phase Distribution

39Total
Not Applicable (17)
Early P 1 (1)
P 1 (3)
P 2 (2)
P 3 (6)
P 4 (10)

Trial Status

Completed27
Unknown14
Terminated3
Recruiting2
Withdrawn2
Active Not Recruiting1

Trial Success Rate

90.0%

Benchmark: 86.5%

Based on 27 completed trials

Clinical Trials (49)

Showing 20 of 20 trials
NCT05428033Phase 3CompletedPrimary

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

NCT05279313Phase 3Active Not RecruitingPrimary

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.

NCT05592119Completed

Effect of Stimulant Medication on Loss of Control Eating in Youth With Attention Deficit/Hyperactivity Disorder

NCT05741307Not ApplicableCompletedPrimary

Effect of a Self-hypnosis on Attention Disorders and Anxiety in Children With Attention Deficit/Hyperactivity Disorder

NCT05721235Phase 4CompletedPrimary

A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

NCT04999982Not ApplicableCompletedPrimary

Pilot Testing PREschooler Care, Community Resources, Advocacy, Referral, Education (PRE-CARE)

NCT05685732Phase 4CompletedPrimary

An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD

NCT05930886RecruitingPrimary

Focus Groups in Ethnically and Racially Diverse Families

NCT06133231Not ApplicableRecruitingPrimary

Optimizing Research With Diverse Families - Feasibility and Acceptability Study (FAST)

NCT03136263Early Phase 1CompletedPrimary

Oxytocin and Cognitive Control in Adult ADHD

NCT04987762Phase 4TerminatedPrimary

Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children

NCT04189575Not ApplicableUnknownPrimary

A Text Messaging (SMS) Intervention to Improve Adherence to Stimulant Medication in Adults With ADHD in the Primary Care Setting

NCT04228094CompletedPrimary

Assesment of TDApp1 an eHelath Tool to Make Therapeutic Recommendations for Patients With ADHD

NCT04189562Not ApplicableUnknownPrimary

A Text Messaging (SMS) Intervention to Improve Adherence to Stimulant Medications in Children With ADHD

NCT04689282Phase 1Completed

Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders

NCT04189536Not ApplicableUnknownPrimary

An SMS Intervention to Improve Adherence to Stimulant Medications in Adults With ADHD

NCT03847402Not ApplicableCompleted

The Early Integrated Intervention for Child Brain-developmental Disorders in China

NCT02333149Phase 3WithdrawnPrimary

Melatonin in Youth: N-of-1 Trials in a Stimulant-treated Attention Deficit Hyperactivity Disorder (ADHD) Population

NCT04152629Phase 4CompletedPrimary

Real World Evidence of the Efficacy and Safety of FOQUEST

NCT01682915CompletedPrimary

Structural and Functional Connectivity of Frontostriatal and Frontoparietal Networks as Endophenotypes of ADHD

Scroll to load more

Research Network

Activity Timeline